Related Experiment Video
Updated: Jan 7, 2026

An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug
Published on: June 4, 2021
Regression of Post-Essential Thrombocythaemia Myelofibrosis with Intermittent Hydroxyurea Therapy: A Case Report
Arumugam Manoharan1, Ian Tang2
1Southern Sydney Haematology, Faculty of Science, Medicine and Health, University of Wollongong, Wollongong, NSW 2500, Australia.
Intermittent hydroxyurea therapy effectively controlled post-essential thrombocythemia myelofibrosis and reduced bone marrow fibrosis. This approach shows promise for myeloproliferative neoplasms, including hydroxyurea-resistant cases.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Essential thrombocythemia can progress to myelofibrosis.
- Myelofibrosis is characterized by bone marrow scarring.
- Hydroxyurea is a standard treatment for myeloproliferative neoplasms.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Hemodialysis II: Procedure and Complications
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
Chronic Kidney Disease II: Clinical Manifestations
Extracorporeal Removal of Drugs: Hemoperfusion and Hemofiltration
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...

